



## MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo

March 12, 2018

LA JOLLA, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will participate in a panel session at the BIO Asia International Conference in Tokyo, Japan on March 19, 2018. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, will speak on the panel, which will discuss partnerships and business development strategies including licensing agreements and alternative deal types.

### Panel session details are as follows:

Date and Time: Monday, March 19, 2018 at 12:30 - 1:25 pm

Session: Globalizing Your Business Development Strategy

Location: Grand Hyatt Tokyo, 6-10-3 Roppongi, Minato-Ku, Tokyo, Japan, 106-0032

### About the BIO Asia International Conference

The BIO Asia International Conference, co-hosted by the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. BIO brings more than ten years of experience and expertise in biotech and pharmaceutical partnering to the Asia-Pacific region, after successfully establishing the largest partnering-focused events in the U.S. and Europe. Dr. Yuichi Iwaki is a member of the BIO Asia advisory committee.

### About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., methamphetamine dependence, opioid dependence, alcohol dependence) and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit [www.medicinova.com](http://www.medicinova.com).

*Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221 and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221 and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2017 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.*

### INVESTOR CONTACT:

Geoff O'Brien  
Vice President  
MediciNova, Inc.  
[info@medicinova.com](mailto:info@medicinova.com)



